Tag: press

WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 72,000 restricted stock units of Arcutis’ common stock to nine newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 2, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Dr. Brian Johnson Introduces Digital Breathing Program Aimed at Enhancing Mindful Focus

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caleres, Inc. (“Caleres” or the “Company”) (NYSE: CAL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

THIS DOCUMENT IS AN UNOFFICIAL ENGLISH-LANGUAGE TRANSLATION OF THE PRESS RELEASE REGARDING THE RESPONSE DOCUMENT (NOTE EN RÉPONSE) WHICH WAS FILED WITH THE FRENCH AUTORITÉ DES MARCHÉS FINANCIERS ON JUNE 5, 2025. IN THE EVENT OF ANY DIFFERENCES BETWEEN THIS UNOFFICIAL ENGLISH- LANGUAGE TRANSLATION AND THE OFFICIAL FRENCH RESPONSE DOCUMENT, THE OFFICIAL FRENCH RESPONSE DOCUMENT SHALL PREVAIL.